What is Zacks Research’s Estimate for COCP FY2026 Earnings?

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Equities research analysts at Zacks Research decreased their FY2026 earnings estimates for shares of Cocrystal Pharma in a research note issued on Monday, June 1st. Zacks Research analyst D. Bautz now expects that the company will earn ($0.76) per share for the year, down from their prior estimate of ($0.73). The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($0.67) per share.

Separately, Weiss Ratings lowered shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $6.00.

Cocrystal Pharma Trading Down 5.4%

NASDAQ:COCP opened at $1.05 on Wednesday. The firm has a market cap of $14.48 million, a price-to-earnings ratio of -1.44 and a beta of 1.42. The company’s 50-day moving average is $1.29 and its two-hundred day moving average is $1.11. Cocrystal Pharma has a 12-month low of $0.86 and a 12-month high of $2.67.

Cocrystal Pharma (NASDAQ:COCP) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The company had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.23 million.

Hedge Funds Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC bought a new stake in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned approximately 0.24% of Cocrystal Pharma as of its most recent filing with the Securities and Exchange Commission (SEC). 6.72% of the stock is currently owned by institutional investors.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.